A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck-Reference-Cited by-同舟云学术

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

Published:2013-03 Issue:3 Volume:24 Page:761-769
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Abdul Razak A.R.,Soulières D.,Laurie S.A.,Hotte S.J.,Singh S.,Winquist E.,Chia S.,Le Tourneau C.,Nguyen-Tan P.- F.,Chen E.X.,Chan K.K.,Wang T.,Giri N.,Mormont C.,Quinn S.,Siu L.L.

Funder

Pfizer

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/3/761/537382/mds503.pdf

Reference37 articles.

1. Head and neck cancer;Argiris;Lancet,2008

2. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck;Argiris;Cancer,2004

3. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393;Forastiere;J Clin Oncol,2001